Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

Official Title

Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer

Summary:

The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.

Trial Description

Primary Outcome:

  • Disease-free survival
Secondary Outcome:
  • Genito-urinary (GU) toxicity

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society